Inspire Investing’s Madrigal Pharmaceuticals MDGL Stock Holding History

Inspire Investing’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$615K	Buy	1,220 +80	+7%	+$42.3K	0.03%	931
2026 Q2	$612K	Buy	+1,140	New	+$584K	0.03%	923
2026 Q1	–	Sell	-2,256	Closed	-$1.31M	–	1143
2025 Q4	$1.31M	Buy	+2,256	New	+$1.15M	0.12%	183
2023 Q3	–	Sell	-1,224	Closed	-$283K	–	855
2023 Q2	$283K	Buy	1,224 +62	+5%	+$16.8K	0.03%	777
2023 Q1	$281K	Buy	+1,162	New	+$317K	0.04%	408

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Inspire Investing's MDGL Position: Q3 2026 in Review

Inspire Investing increased its Madrigal Pharmaceuticals (MDGL) stake by 7% in Q3 2026, buying an estimated $42.3K and bringing the position to 1,220 shares worth $615K. The position accounts for 0.03% of the portfolio, ranked #931.

Inspire Investing first reported a position in MDGL in Q1 2023 and has held it in 5 quarters since. The position peaked at $1.31M in Q4 2025. 180 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Inspire Investing held 1,220 shares of Madrigal Pharmaceuticals worth $615K as of Q3 2026.
Inspire Investing bought 80 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $42.3K.
Madrigal Pharmaceuticals made up 0.03% of Inspire Investing's portfolio in Q3 2026, its #931 holding.
Inspire Investing first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
Inspire Investing's Madrigal Pharmaceuticals position peaked at $1.31M in Q4 2025.
180 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Inspire Investing's 13F filing for Q3 2026, filed 22 Oct 2026.